^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    NLRP3 inhibitor

    Related drugs:
    21d
    Advanced Oxidation Protein Products Aggravate Inflammation of Henoch-Schönlein Purpura Nephritis Through the RAGE-NF-κB Pathway. (PubMed, Clin Lab)
    Collectively, these results implicated that AOPPs may be related to the pathogenesis of HSPN, AOPPs might induce or aggravate inflammation of HSPN through regulating RAGE-NF-κB signaling pathway. Above all, it has important clinical guiding significance for the prognosis judgment of HSPN, and can also provide new therapeutic targets for the HSPN.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    Bay11-7082
    29d
    Study Evaluating ISM8969 in Healthy Adult and Elderly Participants and Obese Adult Participants at Risk of Cardiovascular Disease (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, InSilico Medicine Hong Kong Limited
    New P1 trial
    |
    CRP (C-reactive protein)
    1m
    Caffeic acid phenethyl ester attenuates phenotypic switching and inflammation in abdominal aortic aneurysm via the NF-κB pathway. (PubMed, Mol Biol Rep)
    CAPE mitigates the progression of AAA in mice and counteract the abnormal cell phenotype and inflammatory responses in Ang II-stimulated MOVAS cells. These protective effects might be achieved by inhibiting the NF-κB pathway.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • SPP1 (Secreted Phosphoprotein 1) • BAX (BCL2-associated X protein) • APOE (Apolipoprotein E)
    |
    Bay11-7082
    1m
    A sulfate-arsenical-ferruginous water affects apoptosis, oxidative stress and the gene expression of inflammatory mediators and of a panel of MicroRNA in IL-1β stimulated human osteoarthritic chondrocytes. (PubMed, Front Med (Lausanne))
    The pre-incubation with BAY 11-7082, IKKα/β reduced the damage induced by IL-1β, and, interestingly, potentiated the properties of LW. Our data demonstrated the ability of LW to regulate apoptosis, oxidative stress and gene expression of main factors implicated in OA pathogenesis through a possible modulation of NF-κB signaling pathway. This study supports the use of balneotherapy with a sulfate-arsenical-ferruginous mineral water in the treatment of OA.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR34A (MicroRNA 34a-5p) • IL1B (Interleukin 1, beta) • ACAN (Aggrecan) • COL2A1 (Collagen Type II Alpha 1 Chain) • MIR140 (MicroRNA 140) • MIR181A1 (MicroRNA 181a-1)
    |
    Bay11-7082
    1m
    SERENIA: A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. (clinicaltrials.gov)
    P2, N=124, Recruiting, AstraZeneca
    Trial initiation date
    1m
    An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis (clinicaltrials.gov)
    P2, N=50, Recruiting, Zomagen Biosciences Ltd. | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    1m
    UNITE-ALS: Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis (clinicaltrials.gov)
    P2, N=240, Active, not recruiting, Zydus Therapeutics Inc.
    Trial initiation date
    2ms
    UNITE-ALS: Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis (clinicaltrials.gov)
    P2, N=206, Active, not recruiting, Zydus Therapeutics Inc. | N=152 --> 206
    Enrollment change
    2ms
    Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata (clinicaltrials.gov)
    P2, N=73, Recruiting, NEXTGEN Bioscience | Trial completion date: Jun 2025 --> Jan 2027 | Trial primary completion date: Jun 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    2ms
    A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144 (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, AstraZeneca
    New P1 trial
    2ms
    RIVULET: A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events (clinicaltrials.gov)
    P2, N=162, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    2ms
    UNITE-ALS: Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis (clinicaltrials.gov)
    P2, N=206, Active, not recruiting, Zydus Therapeutics Inc.
    New P2 trial
    |
    NEFL (Neurofilament Light Chain)